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Stress signalingAlcohol intake is associated with myocardial contractile dysfunction and apoptosis although the precise
mechanism is unclear. This study was designed to examine the effect of the cytochrome P450 enzyme
CYP2E1 inhibition on ethanol-induced cardiac dysfunction. Adult male mice were fed a 4% ethanol liquid
or pair-fed control diet for 6 weeks. Following 2 weeks of diet feeding, a cohort of mice started to receive
the CYP2E1 inhibitor diallyl sulﬁde (100 mg/kg/d, i.p.) for the remaining feeding duration. Cardiac function
was assessed using echocardiographic and IonOptix systems. Western blot analysis was used to evaluate
CYP2E1, heme oxygenase-1 (HO-1), iNOS, the intracellular Ca2+ regulatory proteins sarco(endo)plasmic re-
ticulum Ca2+-ATPase, Na+\Ca2+ exchanger and phospholamban, pro-apoptotic protein cleaved caspase-3,
Bax, c-Jun-NH2-terminal kinase (JNK) and apoptosis signal-regulating kinase (ASK-1). Ethanol led to elevated
levels of CYP2E1, iNOS and phospholamban, decreased levels of HO-1 and Na+\Ca2+ exchanger, cardiac con-
tractile and intracellular Ca2+ defects, cardiac ﬁbrosis, overt O2− production, and apoptosis accompaniedwith in-
creased phosphorylation of JNK and ASK-1, the effects were signiﬁcantly attenuated or ablated by diallyl sulﬁde.
Inhibitors of JNK and ASK-1 but not HO-1 inducer or iNOS inhibitor obliterated ethanol-induced cardiomyocyte
contractile dysfunction, substantiating a role for JNK and ASK-1 signaling in ethanol-induced myocardial injury.
Taken together, these ﬁndings suggest that ethanol metabolism through CYP2E1 may contribute to the patho-
genesis of alcoholic cardiomyopathy including myocardial contractile dysfunction, oxidative stress and apopto-
sis, possibly through activation of JNK and ASK-1 signaling.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Chronic ethanol exposure triggers the onset and development of al-
coholic cardiomyopathy characterized by disruption ofmyoﬁbrillary ar-
chitecture and myocardial contractile dysfunction [1–3]. Although a
number of theories have been postulated for ethanol-induced myo-
pathic changes including cardiotoxicity of ethanol and its metabolites,
oxidative stress and accumulation of fatty acid ethyl esters [1–4], the ul-
timate culprit factor(s) behind ethanol-elicited myocardial damage re-
mains elusive. Recent data from our group as well as others have
shown a pivotal role of ethanol metabolism in ethanol-induced cell
and tissue injuries as well as end organ complications such as alcoholic
cardiomyopathy and alcoholic liver diseases [2,5–8]. In particular, muchiatrics, Fourth Military Medical
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l rights reserved.recent attention has been focused on alcohol dehydrogenase (ADH), al-
dehyde dehydrogenase (ALDH), cytochrome P450 2E1 (CYP2E1) and
catalase enzymes, which catalyze ethanol metabolism [9–11]. Ethanol
is metabolized into acetaldehyde by ADH and CYP2E1 in cytoplasm
andmicrosomes, respectively [2]. Convincing evidence fromour labora-
tory aswell as others has depicted a rather important role of ADH in the
onset and progression of alcoholic cardiomyopathy [12–16]. However,
onlymodest ADH inductionwas found following chronic ethanol intake
as a downstream effect of ethanol inhibiting gonadal hormone produc-
tion [17]. Earlier ﬁndings from our laboratory revealed a likely role of
CYP2E1 in ethanol-induced cardiomyocyte contractile defect [18].
CYP2E1 is an enzyme responsible for generation of ROS and reactive
metabolites. With alcohol administration, CYP2E1 is induced resulting
production of ROS and acetaldehyde to contribute to alcoholic liver dis-
eases [5,7]. Recent evidence also depicted a unique role of CYP2E1 in
isoproterenol-induced cardiac dysfunction [19] although direct evi-
dence for a role of CYP2E1 in alcoholic cardiomyopathy is still lacking.
Given the pivotal role of CYP2E1 in ethanol metabolism and oxida-
tive stress [7], the present study was designed to examine the effect of
CYP2E1 inhibitor diallyl sulﬁde on ethanol intake-induced myocardial
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signaling mechanisms involved with a focus on apoptotic stress signal-
ing. The organosulfur compound diallyl sulﬁde has proven effec-
tiveness in the prevention of cancer and chemically-induced
hepatotoxicity possibly through induction of the cytoprotective
protein heme oxygenase-1 (HO-1) as well as suppression of
CYP2E1 and inducible nitric oxide synthase (iNOS) [20,21]. Given
that apoptotic damage is typical following ethanol challenge,
which may play an essential role in ethanol-elicited organ damage
[5,8,22], apoptosis was assessed using TUNEL staining, caspase-3
activity and protein expression of apoptosis-regulatory proteins.
Superoxide (O2−) levels and protein carbonyl formation were mon-
itored as an indicator for oxidative stress. As activation of apoptosis
signaling-regulated kinase (ASK-1) results in activation of
c-Jun-NH2-terminal kinase (JNK), both of which are known to me-
diate ethanol-induced hepatic injury via CYP2E1 enzymatic metab-
olism [23], phosphorylation of JNK and ASK-1 was evaluated in
myocardium from ethanol consuming mice with or without diallyl
sulﬁde treatment. To further evaluate the potential role of ASK-1, JNK,
HO-1 and iNOS in ethanol-induced cardiac anomalies, ethanol-induced
cardiomyocyte contractile response was evaluated in the absence or
presence of inhibitors of ASK-1, JNK and iNOS or the HO-1 inducer.2. Materials and methods
2.1. Chronic ethanol intake and CYP2E1 inhibitor treatment
All animal procedures were conducted in accordance with hu-
mane animal care standards outlined in the NIH Guide for the Care
and Use of Experimental Animals and were approved the University
of Wyoming Animal Care and Use Committee (Laramie, WY). Adult
male FVB mice were housed in a temperature-controlled room
under a 12 h/12 h-light/dark with access to tap water ad libitum.
FVB mice were introduced to a nutritionally complete liquid diet
(Shake & Pour Bioserv Inc., Frenchtown, NJ, USA) for a one-week ac-
climation period. Upon completion of the acclimation period, half of
the mice were maintained on the regular liquid diet (without etha-
nol), and the remaining half began a 6-week period of isocaloric 4%
(vol/vol) ethanol diet feeding. An isocaloric pair-feeding regimen
was employed to eliminate the possibility of nutritional deﬁcits. Con-
trol (non-ethanol consuming) mice were offered the same quantity of
diet ethanol-consuming mice drank the previous day [24]. A cohort of
ethanol consuming or non-consuming mice were administered the
CYP2E1 inhibitor diallyl sulﬁde (100 mg/kg/d, i.p.) starting from
week 3 till the end of diet feeding period [25,26]. Plasma ethanol
levels were measured as described [24]. Systolic and diastolic blood
pressures were recorded using a CODA non-invasive system (Kent
Scientiﬁc Co., Torrington, CT).2.2. Determination of CYP2E1 activity
CYP2E1 activity was assessed using p-nitrophenol (PNP) oxidation
to p-nitrocatechol. In brief, ~1.5 mg of myocardial microsomal pro-
tein was incubated in 1 ml potassium phosphate buffer (100 mM)
containing p-nitrophenol (50 μM) with a pH of 6.8. Reaction was ini-
tiated with addition of NADPH to a concentration of 0.5 mM and
allowed to continue for 10 min at 37 °C. Thereafter, 0.5 volume of
0.5 M perchloric acid was added. Proteins were pelleted by centrifu-
gation (4000 ×g for 15 min). To 1 ml of the supernatant, 100 μl of
10 M NaOH was added, and formed amounts of p-nitrocatechol
were measured by spectrophotometry at 511 nm. A calibration
curve was constructed by subjecting varying amounts (0–100 nmol)
of p-nitrocatechol to the same procedure as the myocardial micro-
somal preparations [20].2.3. Echocardiographic assessment
Cardiac geometry and function were evaluated in anesthetized
(ketamine 80 mg/kg and xylazine 12 mg/kg, i.p.) mice using a 2-D
guided M-mode echocardiography (Sonos 5500) equipped with a
15–6 MHz linear transducer. Left ventricular (LV) wall and chamber
dimensions during diastole and systole were recorded from 3 consec-
utive cycles in M-mode. Fractional shortening was calculated from LV
end-diastolic (EDD) and end-systolic (ESD) diameters using the equa-
tion (EDD-ESD)/EDD. Cardiac output was calculated from LV end-
diastolic and -systolic diameters using the equation [(LVEDD)3−
(LVESD)3]×heart rate. Heart rate was calculated from 10 consecutive
cardiac cycles [27].
2.4. Cardiomyocyte isolation and in vitro drug treatment
After ketamine/xylazine (80 and 12 mg/kg, respectively, i.p.) seda-
tion, hearts were removed and perfused with KHB buffer containing
(in mM): 118 NaCl, 4.7 KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 10
HEPES and 11.1 glucose. Hearts were digested with Liberase for
20 min. Left ventricles were removed and minced before being ﬁltered.
Cardiomyocyte yield was ~75% which was not affected by either etha-
nol or diallyl sulﬁde. Only rod-shaped cardiomyocytes with clear
edges were used for mechanical evaluation [27]. To examine the poten-
tial role of stress signaling, HO-1, and iNOS on ethanol-induced cardiac
response, cardiomyocytes from non-ethanol consuming FVBmice were
treated with ethanol (240 mg/dl) at 37 °C for 4 h in the absence or
presence of the speciﬁc peptide inhibitor of JNK JNKI (2 μM) [28], the
ASK-1 inhibitor thioredoxin-1 (50 μM) [23,29], the HO-1 inducer cobalt
protoporphyrin (CoPP, 25 μM) [30] and the speciﬁc iNOS inhibitor
1400 W (2 μM) [31] prior to the mechanical assessment. The ethanol
concentration (240 mg/dl) was chosen largely based on our earlier
ﬁndings in the cell culture setting [15,32] and the fact that blood alcohol
level may reach 200 mg/dl following chronic drinking in mice [33].
2.5. Cell shortening/relengthening
Mechanical properties of cardiomyocytes were assessed using a
SoftEdge MyoCam® system (IonOptix Corporation, Milton, MA, USA).
Cells were placed in a chambermounted on the stage of an invertedmi-
croscope (Olympus, IX-70) and superfused (~1 ml/min at 25 °C) with a
buffer containing (inmM): 131NaCl, 4 KCl, 1 CaCl2, 1MgCl2, 10 glucose,
and 10 HEPES, at pH 7.4. The cells were ﬁeld stimulated with
supra-threshold voltage at a frequency of 0.5 Hz. The myocyte being
studied was displayed on the computer monitor using an IonOptix
MyoCam camera. An IonOptix SoftEdge software was used to capture
changes in cell length during shortening and relengthening. Cell
shortening and relengthening were assessed using the following in-
dices: peak shortening (PS)—indicative of ventricular contractility,
time-to-PS (TPS)—indicative of contraction duration, and time-to-
90% relengthening (TR90)—represents relaxation duration, maximal
velocities of shortening (+dL/dt) and relengthening (−dL/dt)—
indicatives of maximal velocities of ventricular pressure rise/fall
[27].
2.6. Intracellular Ca2+ transients
Cardiomyocytes were loaded with fura-2/AM (0.5 μM) for 15 min,
and ﬂuorescence intensity was measured with a dual-excitation ﬂuo-
rescence photomultiplier system (IonOptix). Myocytes were placed on
an inverted Olympus microscope and imaged through a Fluor 40×-oil
objective. Cells were exposed to light emitted by a 75 W mercury
lamp and passed through either a 360 nm or a 380 nm ﬁlter. The
myocyteswere stimulated to contract at 0.5 Hz. Fluorescence emissions
were detected between 480 nm and 520 nm by a photomultiplier tube
after cells were ﬁrst illuminated at 360 nm for 0.5 sec and then at
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rate). The 360 nm excitation scanwas repeated at the end of the proto-
col, and qualitative changes in intracellular Ca2+ concentrationwere in-
ferred from the ratio of the ﬂuorescence intensity at two wavelengths.
Intracellular Ca2+ decay rate was calculated from single exponential
curve ﬁtting [22].
2.7. Histological examination
Hearts were harvested and sliced at mid-ventricular level followed
by ﬁxation with normal buffered formalin. Parafﬁn-embedded trans-
verse sections were cut in 5-μm in thickness and stained with Masson
trichrome. Sections were photographed with a 40× objective of an
Olympus BX-51 microscope equipped with an Olympus MaguaFire SP
digital camera. Five random ﬁelds from each section (3 sections per
mouse) were assessed for ﬁbrosis. To determine ﬁbrotic area, pixel
counts of blue stained ﬁbers were quantiﬁed using Color range and His-
togram commands in Photoshop. Fibrotic area was calculated by divid-
ing the pixels of blue stained area to total pixels of non-white area [27].
2.8. TUNEL assay
TUNEL staining of myonuclei positive for DNA strand breaks were
determined using a ﬂuorescence detection kit (Roche, Indianapolis,
IN, USA) and ﬂuorescence microscopy. Parafﬁn-embedded sections
(5 μm) were incubated with Proteinase K solution for 30 min.
TUNEL reaction mixture containing terminal deoxynucleotidyl trans-
ferase (TdT) and ﬂuorescein-dUTP was added to the sections in 50-μl
drops and incubated for 60 min at 37 °C in a humidiﬁed chamber in
the dark. The sections were rinsed three times in PBS for 5 min
each. Following embedding, sections were visualized with an Olym-
pus BX-51 microscope equipped with an Olympus MaguaFire SP dig-
ital camera. DNase I and label solution were used as positive and
negative controls. To determine the percentage of apoptotic cells, mi-
crographs of TUNEL-positive and DAPI-stained nuclei were captured
using an Olympus ﬂuorescence microscope and counted using the
ImageJ software (ImageJ version 1.43r; NIH) followed by manual ex-
clusion of the false-positive staining from 10 random ﬁelds at 400×
magniﬁcation At least 100 cells were counted in each ﬁeld [27].
2.9. Caspase-3 assay
Tissue homogenates were centrifuged (10,000 ×g at 4 °C, 10 min)
and pellets were lysed in an ice-cold cell lysis buffer. The assay was car-
ried out in a 96-well plate with each well containing 30 μl cell lysate,
70 μl of assay buffer (50 mM HEPES, 0.1% CHAPS, 100 mM NaCl,
10 mM DTT and 1 mM EDTA) and 20 μl of caspase-3 colorimetric sub-
strate Ac-DEVD-pNA. The 96-well plate was incubated at 37 °C for
1 h, during which time the caspase in the sample was allowed to cleave
the chromophore p-NA from the substrate molecule. Caspase-3 activity
was expressed as picomoles of pNA released per μg of protein per min-
ute [34].
2.10. Intracellular ﬂuorescence measurement of superoxide (O2
−)
Intracellular O2− was monitored by changes in ﬂuorescence inten-
sity resulting from intracellular probe oxidation [27]. In brief,
cardiomyocytes were loaded with 5 μMdihydroethidium (DHE) (Mo-
lecular Probes, Eugene, OR, USA) for 30 min at 37 °C and washed with
PBS buffer. Cells were sampled randomly using an Olympus BX-51
microscope equipped with an Olympus MagnaFire™ SP digital cam-
era and ImagePro image analysis software (Media Cybernetics, Silver
Spring, MD, USA). Fluorescence was calibrated with InSpeck micro-
spheres (Molecular Probes). An average of 100 cells was evaluated
using the grid crossing method in 15 visual ﬁelds per isolation.2.11. Protein carbonyl assay
To assess cardiac oxidative damage, protein carbonyl content was
determined [35]. In brief, proteins were extracted and minced to pre-
vent proteolytic degradation. Nucleic acids were eliminated by treating
the samples with 1% streptomycin sulfate for 15 min, followed by a
10 min centrifugation (11,000 ×g). Protein was precipitated by adding
an equal volume of 20% TCA to protein (0.5 mg) and centrifuged for
1 min. The TCA solution was removed and the sample resuspended in
10 mM 2,4-dinitrophenylhydrazine (2,4-DNPH) solution. Samples
were incubated at room temperature for 15–30 min. Following a
500 μl of 20% TCA addition, samples were centrifuged for 3 min. The
supernatant was discarded, the pellet washed in ethanol:ethyl acetate
and allowed to incubate at room temperature for 10 min. The samples
were centrifuged again for 3 min and the ethanol:ethyl acetate steps
repeated 2 more times. The precipitate was resuspended in 6 M
guanidine solution, centrifuged for 3 min and insoluble debris removed.
The maximum absorbance (360–390 nm) of the supernatant was
read against appropriate blanks (water, 2 M HCl) and the carbonyl
content was calculated using the molar absorption coefﬁcient of
22,000 M−1 cm−1.
2.12. Western blot analysis
Myocardial protein was prepared as described [34]. Samples
containing equal amount of proteins were separated on 10% SDS-
polyacrylamide gels in a minigel apparatus (Mini-PROTEAN II,
Bio-Rad) and transferred to nitrocellulose membranes. The membranes
were blocked with 5% milk in TBS-T, and were incubated overnight at
4 °C with anti-CYP2E1 (1:1000), anti-HO-1 (1:1000), anti-iNOS
(1:1000), anti-SERCA2a (1:1000), anti-Na+\Ca2+ exchanger (1:1000),
anti-phospholamban (1:1000), anti-phosphorylated phospholamban
(Ser16, 1:1000), anti-cleaved caspase-3 (1:1000), anti-Bax (1:1000),
anti-JNK (1:1000), anti-phosphorylated JNK (pJNK, Thr183/Tyr185,
1:1000), anti-ASK-1 (1:1000), and anti-phosphorylated ASK-1 (pASK-1,
Ser83, 1:1000) antibodies. Anti-SERCA2a was purchased from Afﬁnity
BioReagents (Golden, CO, USA). Anti-phospholamban antibody was pur-
chased from Abcam (Cambridge, MA, USA). All other antibodies were
obtained from Cell Signaling Technology (Beverly, MA, USA). After im-
munoblotting, the ﬁlm was scanned and the intensity of immunoblot
bands was detected with a Bio-Rad Calibrated Densitometer. GAPDH
was used as the loading control.
2.13. Data analysis
Data are Mean±SEM. Difference was calculated by repeated mea-
sures analysis of variance (ANOVA) followed by a Tukey's post hoc
analysis. A p valueb0.05 was considered signiﬁcant.
3. Results
3.1. General biometric and echocardiographic features as well as CYP2E1,
HO-1 and iNOS levels in control and ethanol consuming mice treated
with or without diallyl sulﬁde
Neither ethanol ingestion nor diallyl sulﬁde treatment altered
body and organ weights or organ size (organ-to-body weight ratio).
As expected, chronic ethanol ingestion increased blood alcohol level
and systolic blood pressure without affecting diastolic blood pressure,
the effects of which were unaffected by CYP2E1 inhibition. Heart rate,
left ventricular wall thickness and left ventricular EDD were unaffect-
ed by chronic ethanol intake or diallyl sulﬁde treatment, or both. Eth-
anol intake signiﬁcantly enlarged LV ESD, suppressed fractional
shortening and cardiac output, the effects of which were obliterated
by CYP2E1 inhibition. Diallyl sulﬁde itself did not elicit any notable ef-
fect on echocardiographic properties (Table 1). Consistent with
Table 1
Biometric and echocardiographic parameters of control and alcohol consuming mice.
Parameter Control Ethanol DAS Ethanol–DAS
Body weight (g) 25.2±0.6 25.6±0.7 24.9±0.5 25.6±0.5
Heart weight (mg) 140±5 140±4 138±5 141±4
Heart/body weight (mg/g) 5.57±0.19 5.51±0.13 5.56±0.16 5.49±0.07
Liver weight (g) 1.31±0.05 1.32±0.02 1.31±0.03 1.34±0.03
Liver/body weight (mg/g) 51.8±1.5 51.9±2.1 52.7±1.2 52.3±0.8
Kidney weight (mg) 317±10 324±15 314±10 333±12
Kidney/body weight (mg/g) 12.6±0.3 12.7±0.6 12.6±0.3 13.0±0.4
Diastolic blood pressure (mm Hg) 79.4±1.9 78.7±1.8 78.4±1.8 79.0±1.7
Systolic blood pressure (mm Hg) 112.2±2.1 125.2±2.2* 109.9±2.1 125.1±2.7*
Blood alcohol level (mg/dl) Undetectable 73.2±4.5* Undetectable 77.2±4.8*
Heart rate (bpm) 451±12 447±12 460±13 460±12
LV wall thickness (mm) 0.98±0.03 0.95±0.04 0.94±0.03 0.95±0.04
LV ESD (mm) 1.29±0.05 1.53±0.04* 1.34±0.04 1.33±0.06#
LV EDD (mm) 2.56±0.11 2.44±0.04 2.61±0.11 2.56±0.15
Factional shortening (%) 49.3±1.7 37.1±1.5* 47.7±1.9 47.5±1.5#
Cardiac output (mm3min) 7447±926 4939±357* 7434±914 7563±1221#
LV: left ventricular; LV ESD: LV end systolic diameter; LV EDD: LV end diastolic diameter; Mean±SEM, n=9–10 mice per group, undetectable: b2.5 mg/dl, *pb0.05 vs. control
group, #pb0.05 vs. ethanol group.
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upregulated protein expression and enzymatic activity of CYP2E1
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Ethanol intake signiﬁcantly prolonged the resting cell length, the
effect of which was ablated by diallyl sulﬁde treatment. Diallyl sulﬁde
did not affect resting cell length by itself. Chronic ethanol intake sig-
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Fig. 3. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced intracellular Ca2+ handling derangement. Mice were fed control or
ethanol (4%) diet for 6 weeks prior to intracellular Ca2+ measurement. Cohorts of ethanol consuming or non-consuming mice were administered DAS stating from week 3 till the end
of feeding period. A: Resting fura-2 ﬂuorescence intensity (FFI); B: Peak FFI; C: Electrically-stimulated rise in FFI (ΔFFI); and D: Intracellular Ca2+ decay rate. Mean±SEM, n=91–92
cells from 4 mice per group, *pb0.05 vs. control group, #pb0.05 vs. ethanol group.
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ther ethanol intake nor CYP2E1 inhibition, or both, signiﬁcantly af-
fected cardiomyocyte transverse cross-section area. Our data from
Masson trichrome staining further revealed overt myocardial ﬁbro-
sis following chronic ethanol intake, the effect of which was signiﬁ-
cantly attenuated by CYP2E1 inhibition with little effect of diallyl
sulﬁde itself (Fig. 4).
Ethanol intake is often associated with enhanced apoptosis [34].
To assess the impact of diallyl sulﬁde on cell survival and oxidative
stress following ethanol intake, myocardial apoptosis and oxidative
stress were evaluated using TUNEL staining, capase-3 assay, mito-
chondrial O2− production and protein carbonyl formation. Our data
shown in Fig. 5 revealed that chronic ethanol intake promoted myo-
cardial apoptosis as evidenced by the TUNEL-positive nuclei visual-
ized in ﬂuorescein green (as a percentage of all nuclei stained with
DAPI) and capase-3 activity, the effect of which was signiﬁcantly at-
tenuated by diallyl sulﬁde. Likewise, chronic ethanol intake signiﬁ-
cantly promoted O2− production and protein carbonyl formation in
the heart, which was signiﬁcantly attenuated or ablated by CYP2E1
inhibition (Fig. 6). The CYP2E1 inhibitor itself did not elicit any
overt effect on apoptosis, O2− production and protein carbonyl
formation.
3.4. Impact of diallyl sulﬁde on ethanol-induced change in intracellular
Ca2+ regulator proteins
To explore the possiblemechanismbehinddiallyl sulﬁde and/or eth-
anol intake-induced responses on cardiac contractile function and intra-
cellular Ca2+ homeostasis, western blot was performed to assess thelevels of the essential intracellular Ca2+ regulatory proteins SERCA2a,
Na+\Ca2+ exchanger and phospholamban. Our data revealed that eth-
anol intake signiﬁcantly downregulated Na+\Ca2+ exchanger and
upregulated phospholamban expression without affecting SERCA2a
level and phospholamban phosphorylation. Although the CYP2E1 in-
hibitor itself did not affect the levels of these Ca2+ regulatory proteins
(or phospholamban phosphorylation), it obliterated chronic ethanol
intake-induced changes in Na+\Ca2+ exchanger and phospholamban
levels without affecting SERCA2a and phospholamban phosphorylation
(Fig. 7).
3.5. Diallyl sulﬁde on ethanol challenge-induced changes in apoptotic
protein makers
In line with the ﬁndings from TUNEL staining and caspase-3 assay,
our results further indicated that ethanol intake signiﬁcantly in-
creased expression of the pro-apoptotic proteins Bax and cleaved
caspase-3 as well as phosphorylation of the pro-apoptotic stress sig-
naling JNK and ASK-1 (absolute or normalized value) without affect-
ing their pan protein expressions. Although diallyl sulﬁde itself failed
to alter the expression or phosphorylation of these pro-apoptotic pro-
teins, it signiﬁcantly attenuated or ablated ethanol-elicited responses
in cleaved caspase-3, Bax, JNK and ASK-1 (Fig. 8).
3.6. Role of JNK and ASK-1 signaling in ethanol-induced cardiomyocyte
mechanical responses
To consolidate a role of JNK and ASK-1 in ethanol-induced
cardiomyocyte anomalies, we re-examined cardiomyocyte contractile
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Fig. 4. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced histological changes. Mice were fed control or ethanol (4%) diet
for 6 weeks prior to histological assessment. Cohorts of ethanol consuming or non-consuming mice were administered DAS (weeks 3–6). A–D: Representative H&E micrographs
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andASK-1. Ourﬁndings revealed that inhibition of JNK andASK-1 signal-
ing cascades using the JNK peptide inhibitor JNKI and thioredoxin-1, re-
spectively, abolished acute ethanol exposure-induced depression in
peak shortening and±dL/dt as well as prolongation in TR90 without af-
fecting resting cell length and TPS. Neither JNKI nor thioredoxin-1 affect-
ed cardiomyocyte mechanics by themselves (Fig. 9).3.7. Role of HO-1 and iNOS in ethanol-induced cardiomyocyte mechanical
responses
To assess if HO-1 and iNOS play a role in ethanol-induced
cardiomyocyte anomalies, we evaluated cardiomyocyte contractile
properties in the absence or presence of the HO-1 inducer cobalt proto-
porphyrin or the speciﬁc iNOS inhibitor 1400 W. Result depicted in
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Fig. 5. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced myocardial apoptosis. Mice were fed control or ethanol (4%) diet
for 6 weeks prior to assessment of apoptosis. A–D: Photomicrograph showing TUNEL staining in myocardium from mice fed control or ethanol diet with or without DAS treatment.
TUNEL positive nuclei were visualized with ﬂuorescein (green). A: Control; C: Ethanol; C: DAS; and D: Ethanol-DAS. All nuclei were stained with DAPI shown in blue color; E: Pooled
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135R.-H. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 128–141Fig. 10 revealed that neither induction of HO-1 nor inhibition of iNOS
signiﬁcantly affected ethanol exposure-induced cardiomyocyte con-
tractile anomalies (shown as depressed peak shortening and ±dL/dt
as well as prolonged TR90 along with unchanged TPS). Neither cobalt
protoporphyrin nor 1400 W affected cardiomyocyte mechanics by
themselves.
4. Discussion
The major ﬁndings of our study revealed that CYP2E1 inhibition
rescued against lowered cardiac output, myocardial contractile dys-
function, intracellular Ca2+ mishandling and apoptosis following
chronic ethanol intake. This is in line with the fact that diallyl sulﬁde
mitigated chronic ethanol intake-induced rise in the level and enzy-
matic activity of CYP2E1 as reported in the liver [20,38]. Data from
our study revealed elevated myocardial O2− production, protein car-
bonyl formation, myocardial ﬁbrosis and activation of the stress sig-
naling JNK and ASK-1 following ethanol intake, the effects of which
were attenuated or mitigated by diallyl sulﬁde, suggesting a role ofoxidative stress, ﬁbrosis and apoptosis in CYP2E1 inhibition-elicited
beneﬁcial myocardial effect against ethanol intake. Furthermore, our
in vitro experiments further supported a role of JNK and ASK-1 in
ethanol-elicited cardiac contractile anomalies. Taken together, these
observations revealed, for the ﬁrst time, that ethanol metabolism
through CYP2E1 contributes to the development of alcoholic cardio-
myopathy, indicating the promises of CYP2E1 inhibition in the man-
agement of alcoholic cardiomyopathy.
Development of alcoholic cardiomyopathy is characterized by
compromised myocardial pump function [5,7,8,22,28]. Our data re-
vealed that 6 weeks of ethanol intake lowered cardiac output, triggered
cardiac contractile dysfunction, intracellular Ca2+ derangement, ox-
idative stress and apoptosis, in a manner similar to our previous re-
ports using either binge drink or longer-term ethanol intake
[3,12,13,24,34,39]. Our six-week ethanol intake regimen failed to re-
veal cardiac hypertrophy as those seen in longer periods of ethanol in-
take [16,23,29]. This is supported by unchanged resting cardiomyocyte
cell length and cross-sectional area. In our hand, chronic ethanol expo-
sure lowered cardiac output, elevated systolic blood pressure without
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Fig. 6. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced O2− production and protein carbonyl formation. Mice were fed
control or ethanol (4%) diet for 6 weeks prior to assessment of DHE ﬂuorescence. Cohorts of ethanol consuming or non-consuming mice were administered DAS stating from week
3. A–D: Representative ﬂuorescence images (40×) from control, ethanol, DAS and ethanol-DAS groups; E: Pooled data; and F: Protein carbonyl level. Mean±SEM, n=9 ﬁelds
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diallyl sulﬁde. The discrepancy between cardiac and vascular effects
in response to ethanol exposure and diallyl sulﬁde treatment is not
fully clear although it may be speculated that certain hemodynamic
or neurohormonal factors (such as neurotransmitters) may contrib-
ute to the regulation of cardiovascular function following chronic
ethanol exposure.
Excessive ethanol intake is known to trigger oxidative stress and ap-
optosis via activation of stress signaling [40,41]. This is supported by our
ﬁndings of elevated O2− production, protein carbonyl formation,
TUNEL-staining, caspase-3 activity as well as expression of cleaved
caspase-12 and Bax in murine hearts following chronic ethanol intake.
Enhanced O2− and oxidative stress are well known to promote cardiac
contractile and intracellular Ca2+ abnormalities as well as interstitialﬁbrosis [42,43]. It has been demonstrated that ethanol may promote
free radical generation through direct and indirect mechanisms such
as aldehyde oxidase and xanthine oxidase-mediated oxidation, leading
to accumulation of O2− and oxidative stress [44]. On the other hand, the
occurrence of apoptosis such as seen in our study contributes to loss of
cardiomyocytes, and may serve as a predictor of adverse outcomes for
cardiac diseases and eventually heart failure [43]. Like many other car-
diovascular diseases such as atherosclerosis, myocardial ischemia and
reperfusion injury, and diabetic cardiomyopathy, apoptosis plays a piv-
otal role in the pathogenesis of alcoholic cardiomyopathy [43]. In this
study, the up-regulated expression of caspase-3 and Bax, as well as in-
creased TUNEL positive cells and caspase-3 activity depicted the pres-
ence of a global myocardial apoptosis following chronic ethanol
intake. Our intracellular Ca2+ results suggested that cardiacmechanical
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Fig. 7. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced changes in intracellular Ca2+ regulatory proteins. Mice were fed
control or ethanol (4%) diet for 6 weeks prior to collection of tissues for Western blot analysis. Cohorts of ethanol consuming or non-consuming mice were administered DAS stat-
ing from week 3. A: SERCA2a; B: Na+\Ca2+ exchanger; C: Phospholamban; and D: phosphorylated phospholamban; Insets: Representative gels depicting intracellular Ca2+ reg-
ulatory proteins using speciﬁc antibodies. GAPDH was used as the loading control. Mean±SEM, n=4–6 mice per group, *pb0.05 vs. control group, #pb0.05 vs. ethanol group.
137R.-H. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 128–141dysfunction following chronic ethanol intake may be underscored by
ethanol-induced intracellular Ca2+ derangements (decreased ΔFFI
and prolonged intracellular Ca2+ decay), consistent with the notion of
an essential role for impaired intracellular Ca2+ homeostasis in the
pathogenesis of alcoholic cardiomyopathy [3,39]. This is supported by
downregulated Na+\Ca2+ exchanger and upregulated levels of the
SERCA-inhibitory protein phospholamban following ethanol intake.
Perhaps the most striking piece of ﬁndings from our study was
that CYP2E1 inhibition attenuated or abolished chronic ethanol
intake-induced myocardial anomalies. Although CYP2E1-mediated
ethanol metabolism has been proved to play an essential role in alco-
holic liver injury [5,7,20,38], our study presented the ﬁrst piece of ev-
idence that CYP2E1 inhibition is capable of retarding or preventing
the progression of alcoholic cardiomyopathy. Several scenarios may
be considered to attribute to the beneﬁcial effects of diallyl sulﬁde
against alcoholism. First, diallyl sulﬁde may elicit its beneﬁcial effects
via alleviating free radicals and anti-apoptosis. CYP2E1 inhibition ef-
fectively alleviates ethanol intake-induced oxidative stress and apo-
ptosis, en route to preserve cardiac function. This is supported by
our current ﬁnding that diallyl sulﬁde attenuated ethanol exposure-
induced myocardial protein carbonyl formation and that fact that an-
tioxidant protects against development of alcoholic cardiomyopathy
[45]. Second, ethanol intake was found to promote phosphorylationof JINK and ASK-1, two pivotal pro-apoptotic signaling molecules. In-
terestingly, CYP2E1 inhibition ablated or attenuated ethanol-induced
phosphorylation of JNK and ASK-1 substantiated a critical role of
pro-apoptotic stress signaling in CYP2E1-mediated protection against
ethanol-induced cardiac injury. MAP kinases such as JNK have been
shown to play an crucial role in CYP2E1-mediated alcoholic hepatic
toxicity [46]. Recent evidence has identiﬁed ASK-1, a member of
MAP kinase kinase kinase (MAP3K), as an upstream signaling mole-
cule for JNK that is activated in response to oxidative stress, ER stress
and pro-inﬂammatory cytokines such as TNF-α [46]. At resting state,
ASK-1 may form an inactive complex with reduced thioredoxin, thus
making thioredoxin-1 a natural inhibitor for ASK-1 [47]. Our recent
study using a chronic ethanol intake regimen revealed activation of
ASK-1 in the heart [35], consistent with the present observation.
Data from our study revealed that diallyl sulﬁde negated ethanol
exposure-induced changes in myocardial HO-1 and iNOS expression,
consistent with those reported in the liver [20]. These ﬁndings fa-
vored a possible role of HO-1 and iNOS in alcoholic cardiac injury.
HO-1 and iNOS are known to be down- and upregulated, respective-
ly, by ethanol exposure [20,38]. Nonetheless, our ﬁnding that HO-1
induction and iNOS inhibition failed to reconcile ethanol exposure-
induced cardiomyocyte anomalies does not support a major role of
HO-1 and iNOS in alcoholic cardiomyopathy.
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Fig. 8. Effect of the CYP2E1 inhibitor diallyl sulﬁde (DAS, 100 mg/kg/d, i.p., for 4 weeks) on ethanol intake-induced changes in pro-apoptotic stress signaling. Mice were fed control or ethanol
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Fig. 9. Effect of the ASK-1 inhibitor thioredoxin-1 (TRX-1, 50 μM) and the JNK speciﬁc peptide inhibitor JNKI (2 μM) on ethanol exposure (240 mg/dl, 4 h)-induced cardiomyocyte
contractile dysfunction. A: Resting cell length; B: Peak shortening (PS, normalized to cell length); C:Maximal velocity of shortening (+dL/dt); D:Maximal of relengthening (−dL/dt);
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139R.-H. Zhang et al. / Biochimica et Biophysica Acta 1832 (2013) 128–141In summary, data from our study provided evidence that CYP2E1
inhibition may counteract chronic ethanol intake-induced myocardial
contractile dysfunction, intracellular Ca2+ mishandling, oxidative
stress and apoptosis, favoring a role of cytochrome P-450 in ethanol-
elicit alcoholic cardiomyopathy. CYP2E1 is involved in themetabolism
of small molecule substrates such as ethanol, drugs and carcinogens
[7,46]. Recent focus on CYP2E1 revolves around its unique ability to
metabolize and activate many toxicologically important compounds
including ethanol, carbon tetrachloride, acetaminophen, halothane,
benzene, and many other halogenated substrates [7,46]. Toxicity of
these small molecules may be exacerbated following induction of
CYP2E1 by ethanol exposure while getting reduced by inhibitors ofCYP2E1 or CYP2E1 knockout [7,46]. Moreover, CYP2E1 enzyme in par-
ticular hepatic CYP2E1 can be induced by various pathological insults
such as type 2 diabetes, obesity and ethanol intoxication, where pres-
ence of high CYP2E1 levels within the mitochondria may be deleteri-
ous to facilitate the condition of oxidative stress [5,46]. Data from
our present study should shed some lights towards a better under-
standing of the role of cytochrome P-450 pathway in myocardial pa-
thology under alcoholism and other conditions.
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Fig. 10. Effect of the HO-1 inducer cobalt protoporphyrin (CoPP, 25 μM) and the iNOS inhibitor 1400 W (2 μM) on ethanol exposure (240 mg/dl, 4 h)-induced cardiomyocyte con-
tractile dysfunction. A: Resting cell length; B: Peak shortening (PS, normalized to cell length); C: Maximal velocity of shortening (+dL/dt); D: Maximal of relengthening (−dL/dt);
E: Time-to-PS (TPS) and F: Time-to-90% relengthening (TR90). Mean±SEM, n=46 cells from 2 mice per group, *pb0.05 vs. control group.
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